14.45
-0.02 (-0.14%)
| Penutupan Terdahulu | 14.47 |
| Buka | 14.59 |
| Jumlah Dagangan | 2,028,495 |
| Purata Dagangan (3B) | 1,816,922 |
| Modal Pasaran | 2,333,328,128 |
| Harga / Pendapatan (P/E Ke hadapan) | 31.25 |
| Harga / Jualan (P/S) | 5.89 |
| Harga / Buku (P/B) | 2.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 |
| Margin Keuntungan | -3.13% |
| Margin Operasi (TTM) | 14.40% |
| EPS Cair (TTM) | -0.080 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.46% |
| Nisbah Semasa (MRQ) | 2.13 |
| Aliran Tunai Operasi (OCF TTM) | 80.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 67.68 M |
| Pulangan Atas Aset (ROA TTM) | 0.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -1.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | Certara, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.75 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.32% |
| % Dimiliki oleh Institusi | 96.93% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Brown Brothers Harriman & Co | 31 Dec 2024 | 3,818,613 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Keybanc, 24.57%) | Beli |
| Median | 15.00 (3.81%) | |
| Rendah | 11.00 (Barclays, -23.88%) | Pegang |
| Purata | 14.75 (2.08%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 12.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Keybanc | 16 Apr 2025 | 18.00 (24.57%) | Beli | 13.53 |
| Baird | 11 Apr 2025 | 13.00 (-10.03%) | Pegang | 12.91 |
| Barclays | 10 Apr 2025 | 11.00 (-23.88%) | Pegang | 10.51 |
| 28 Feb 2025 | 13.00 (-10.03%) | Pegang | 11.98 | |
| Stephens & Co. | 27 Feb 2025 | 17.00 (17.65%) | Beli | 12.40 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Apr 2025 | Pengumuman | Certara to Participate in Upcoming Investor Conferences |
| 14 Apr 2025 | Pengumuman | Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing |
| 14 Apr 2025 | Pengumuman | Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization |
| 01 Apr 2025 | Pengumuman | Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities |
| 05 Mar 2025 | Pengumuman | Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions |
| 26 Feb 2025 | Pengumuman | Certara Reports Fourth Quarter 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |